Comparative Efficacy of Chinese Herbal Injections for Treating Pediatric Bronchopneumonia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

Xiaojiao Duan; Haojia Wang; Jiarui Wu; Yubo Guo; Kaihuan Wang; Xinkui Liu; Zeng Xiantao; Xiaomeng Zhang

doi:10.1155/2020/6127197

Comparative Efficacy of Chinese Herbal Injections for Treating Pediatric Bronchopneumonia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

Evid Based Complement Alternat Med. 2020 May 23:2020:6127197. doi: 10.1155/2020/6127197. eCollection 2020.

Authors

Xiaojiao Duan^{1

2}, Haojia Wang¹, Jiarui Wu¹, Yubo Guo², Kaihuan Wang¹, Xinkui Liu¹, Zeng Xiantao³, Xiaomeng Zhang¹

Affiliations

¹ Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, China.
² Standardization Department, China Association of Chinese Medicine, Beijing 100029, China.
³ Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.

Abstract

Introduction: Pediatric bronchopneumonia is one of the common respiratory diseases in pediatrics. Chinese herbal injections (CHIs) are widely used to treat pediatric bronchopneumonia. In this study, we examined the efficacy of CHIs in the treatment of pediatric bronchopneumonia using a network meta-analysis (NMA).

Methods: Randomized controlled trials (RCTs) of CHIs combined western medicine (WM) versus WM were searched from electronic databases. WinBUGS 1.4.3 and Stata 13.0 were adopted to compute calculations and prepare graphs, respectively.

Results: 168 RCTs with 21917 patients were included. The results revealed that Xixinnao injection (XXN) + WM had the most probability to be the best intervention in the four aspects of rate of clinical efficacy, antipyretic time, cough disappearance time, and lung shadow disappearance time. While as to lung shadow disappearance time, asthma disappearance time, and hospitalization time, Yanhuning injection (YHN) + WM could be the best intervention. The safety of CHIs needs to be further assessed.

Conclusions: Based on this NMA, XXN + WM and YHN + WM were potential optimal therapies in pediatric bronchopneumonia, and their safety should be strictly monitored.

Publication types

Review